Document 0643
 DOCN  M9480643
 TI    Impact of HIV infection on non-AIDS mortality among Italian injecting
       drug users.
 DT    9410
 AU    Zaccarelli M; Gattari P; Rezza G; Conti S; Spizzichino L; Vlahov D;
       Ippolito G; Lelli V; Valenzi C; Drug Treatment Centre and AIDS Unit
       USL-RM10, Rome, Italy.
 SO    AIDS. 1994 Mar;8(3):345-50. Unique Identifier : AIDSLINE MED/94304555
 AB    OBJECTIVES: To estimate the excess mortality of injecting drug users
       (IDU) stratified by HIV serostatus compared with the general population
       in Italy. To compare total and cause-specific mortality in HIV-positive
       versus HIV-negative IDU, in order to identify possible HIV-related
       non-AIDS causes of death in this population. METHODS: All IDU attending
       two drug-treatment centres in Rome who underwent HIV testing between
       1985 and 1991 were enrolled into a prospective study. The end-point of
       the study was death from any cause by 31 December 1991. Mortality rates
       were compared using age-adjusted standardized mortality ratios and
       person-time techniques. RESULTS: Of the 2431 IDU, 1661 (68.3%) were
       HIV-seronegative and 82 seroconverted. Of 181 deaths, comprising 89 from
       AIDS and 92 from other causes, the mortality rate was 4.5 and 0.8 per
       100 person-years in HIV-seropositives and HIV-seronegatives,
       respectively. For non-AIDS mortality in HIV-seropositives, the overall
       rate was 1.7 per 100 person-years. Deaths from overdose and
       endocarditis/embolus tended to be higher in HIV-seropositive than
       HIV-seronegative IDU, although there was no difference in the rate of
       deaths due to pneumonia by HIV serostatus. CONCLUSIONS: These data are
       consistent with other studies demonstrating a higher frequency of
       mortality among HIV-seropositive IDU. The excess in overdose mortality
       among HIV-seropositives is disturbing and merits further investigation.
 DE    Adult  Cohort Studies  Female  Human  HIV Infections/*COMPLICATIONS  HIV
       Seronegativity  HIV Seropositivity/COMPLICATIONS  Male
       Overdose/COMPLICATIONS/MORTALITY  Prospective Studies  Rome/EPIDEMIOLOGY
       Substance Abuse, Intravenous/*COMPLICATIONS/*MORTALITY  Support,
       Non-U.S. Gov't  Survival Analysis  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).